Enzymatics this week launched a targeted sequencing assay today for detecting and identifying fusions of 26 genes associated with sarcoma.
Using Enzymatics' proprietary anchored multiplex PCR-based enrichment, fusions of all genes in their panel can be identified in a single sequencing run, even without prior knowledge of fusion partners or breakpoints, the company said. The assay will join the ALK, RET, ROS1 v2 panel and the Heme panel as the newest addition to the Archer FusionPlex product line.
FusionPlex assays are target-enrichment assays used to create libraries for next-generation sequencing. They are FFPE-compatible, can be run on Illumina and Ion Torrent NGS platforms, and, in conjunction with Archer Universal RNA Fusion Detection Kits and MBC Adapters, can simultaneously detect and identify specific gene fusions, the company said.